<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-23T21:22:29Z</responseDate><request verb="GetRecord" identifier="oai:uvadoc.uva.es:10324/45301" metadataPrefix="rdf">https://uvadoc.uva.es/oai/request</request><GetRecord><record><header><identifier>oai:uvadoc.uva.es:10324/45301</identifier><datestamp>2021-06-24T07:25:59Z</datestamp><setSpec>com_10324_41462</setSpec><setSpec>com_10324_954</setSpec><setSpec>com_10324_894</setSpec><setSpec>col_10324_41463</setSpec></header><metadata><rdf:RDF xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
<ow:Publication rdf:about="oai:uvadoc.uva.es:10324/45301">
<dc:title>Impact of the rotavirus vaccine in Valladolid, Spain: An interrupted time series analysis</dc:title>
<dc:creator>Pérez Rubio, Alberto</dc:creator>
<dc:creator>Luquero Alcalde, Francisco Javier</dc:creator>
<dc:creator>Bachiller Luque, María Rosario</dc:creator>
<dc:creator>Torre Pardo, Paz de la</dc:creator>
<dc:creator>Eiros Bouza, José María</dc:creator>
<dc:description>Producción Científica</dc:description>
<dc:description>Rotavirus vaccines (RV) have decreased the infant morbidity and mortality in countries that included RV&#xd;
in their national schedule. Rotavirus vaccination is recommended by the Spanish Society of Pediatrics;&#xd;
however, Spain, as most countries in Europe, has authorized commercialization but not included RV in&#xd;
its national vaccination program. We assessed the impact of RV on the rotavirus hospitalization rate&#xd;
through an interrupted time series analysis. There was a 46.8% (95% CI: 29.3–60.2) decrease on the rotavirus&#xd;
hospitalizations rate in the study region after RV commercialization in 2006. Currently there is limited&#xd;
evidence about the impact of RV in Europe, especially among countries not offering systematic&#xd;
vaccination in their national schedule. Documentation of RV coverage, effectiveness and impact is&#xd;
urgently needed in these countries.</dc:description>
<dc:date>2021-02-18T11:56:26Z</dc:date>
<dc:date>2021-02-18T11:56:26Z</dc:date>
<dc:date>2016</dc:date>
<dc:type>info:eu-repo/semantics/article</dc:type>
<dc:identifier>Trials in Vaccinology, 2016, vol. 5, p. 84-87</dc:identifier>
<dc:identifier>1879-4378</dc:identifier>
<dc:identifier>http://uvadoc.uva.es/handle/10324/45301</dc:identifier>
<dc:identifier>10.1016/j.trivac.2016.04.005</dc:identifier>
<dc:identifier>84</dc:identifier>
<dc:identifier>87</dc:identifier>
<dc:identifier>Trials in Vaccinology</dc:identifier>
<dc:identifier>5</dc:identifier>
<dc:language>eng</dc:language>
<dc:relation>https://www.sciencedirect.com/science/article/pii/S1879437816300109</dc:relation>
<dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
<dc:rights>http://creativecommons.org/licenses/by-nc-nd/4.0/</dc:rights>
<dc:rights>© 2016 Published by Elsevier Ltd.</dc:rights>
<dc:rights>Attribution-NonCommercial-NoDerivatives 4.0 Internacional</dc:rights>
<dc:publisher>Elsevier</dc:publisher>
<dc:peerreviewed>SI</dc:peerreviewed>
</ow:Publication>
</rdf:RDF></metadata></record></GetRecord></OAI-PMH>